Catalent, Inc. (NYSE: CTLT) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
FDA (Food and Drug Administration) Drug Approval Process Training Course: Comprehensive Programme Covering Procedures for Submission of INDs, NDAs, ANDAs and 505(b)(2) (LIVE ONLINE EVENT/ON-DEMAND) [Yahoo! Finance]
Melt Pharmaceuticals Reports Positive Phase 3 Topline Efficacy Results for MELT-300, Its Lead Product Candidate for Opioid-Free, Sublingual Procedural Sedation in Patients Undergoing Cataract Surgery [Yahoo! Finance]
Matica Biotechnology Appoints Life Sciences Leader Min Park, MBA to Chief Commercial Officer [Yahoo! Finance]
Pharmaceutical Outsourcing Launches New Clinical Trials Documentary: Transforming Drug Development: Accelerating Clinical Trials through Patient-Centric Innovations and Technological Breakthroughs [Yahoo! Finance]